The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?

被引:24
|
作者
Hahn, Felix [1 ]
Mueller, Lukas [1 ]
Stoehr, Fabian [1 ]
Maehringer-Kunz, Aline [1 ]
Schotten, Sebastian [1 ]
Dueber, Christoph [1 ]
Bartsch, Fabian [2 ]
Lang, Hauke [2 ]
Galle, Peter R. [3 ]
Weinmann, Arndt [3 ,4 ]
Kloeckner, Roman [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Diagnost & Intervent Radiol, Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Gen Visceral & Transplant Surg, Mainz, Germany
[3] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Internal Med, Mainz, Germany
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, CRU, Mainz, Germany
关键词
ICC; Intrahepatic cholangiocarcinoma; PMI; sarcopenia; survival; VISCERAL ADIPOSITY; RESECTION; SURVIVAL; OUTCOMES; IMPACT; COMPLICATIONS; HEPATECTOMY; QUALITY; CANCERS; PREDICT;
D O I
10.1111/liv.14132
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims Sarcopenia has emerged as a prognostic parameter in numerous cancer entities. Current research favours its role as a determining factor for overall survival (OS) in patients with intrahepatic cholangiocarcinoma (ICC); however, it is unclear whether sarcopenia is a truly independent survival predictor if combined with established prognostic factors. Methods Between 1997-2018, 417 patients with histopathologically confirmed ICC were referred to our centre, of whom 293 were included in this study. Cross-sectional imaging, laboratory examinations and histopathological reports were retrospectively analysed. Psoas muscle index (PMI) as easy-to-measure marker of sarcopenia was calculated. Using optimal stratification, sex-specific PMI cut-offs were calculated and tested in hazard regression models against previously published risk factors-for the entire cohort, and within resected and non-resected subgroups. Results Median OS for patients with low respectively high PMI was 23.5 and 34.5 months in the resected subgroup (P = 0.008) and 5.1 and 7.8 months (P = 0.01) in the non-resected subgroup. In multivariate hazard regression models for the entire cohort, low PMI exhibited independent predictive value (P = 0.01) as did translobar tumour spread (P = 0.005), extrahepatic extension (P = 0.03), tumour boundary type (P < 0.001), carbohydrate antigen 19-9 (CA 19-9) levels (P = 0.001), alkaline phosphatase levels (P = 0.001) and distant metastasis (P < 0.001). In subgroup analyses, low PMI remained predictive among non-resected patients (P = 0.03), but lost its predictive value among resected patients (P = 0.15). Conclusions Psoas muscle index strongly predicted OS in univariate analysis. However, addition of established risk factors eliminated its predictive value among resected patients. Thus, when resection is deemed oncologically reasonable, patients should not be excluded from surgery because of sarcopenia alone.
引用
收藏
页码:1307 / 1314
页数:8
相关论文
共 50 条
  • [21] Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment
    Katsuya Toshida
    Shinji Itoh
    Yuki Nakayama
    Yuriko Tsutsui
    Yukiko Kosai-Fujimoto
    Takahiro Tomino
    Shohei Yoshiya
    Yoshihiro Nagao
    Noboru Harada
    Kenichi Kohashi
    Yoshinao Oda
    Tomoharu Yoshizumi
    International Journal of Clinical Oncology, 2023, 28 : 1082 - 1091
  • [22] Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment
    Toshida, Katsuya
    Itoh, Shinji
    Nakayama, Yuki
    Tsutsui, Yuriko
    Kosai-Fujimoto, Yukiko
    Tomino, Takahiro
    Yoshiya, Shohei
    Nagao, Yoshihiro
    Harada, Noboru
    Kohashi, Kenichi
    Oda, Yoshinao
    Yoshizumi, Tomoharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (08) : 1082 - 1091
  • [23] EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma
    Xiao-Yi Hao
    Jian-Peng Cai
    Xin Liu
    Wei Chen
    Xun Hou
    Dong Chen
    Jia-ming Lai
    Li-Jian Liang
    Xiao-Yu Yin
    ChineseJournalofCancer, 2016, 35 (08) : 421 - 429
  • [24] EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma
    Hao, Xiao-Yi
    Cai, Jian-Peng
    Liu, Xin
    Chen, Wei
    Hou, Xun
    Chen, Dong
    Lai, Jia-ming
    Liang, Li-Jian
    Yin, Xiao-Yu
    CHINESE JOURNAL OF CANCER, 2016, 35 : 70
  • [25] Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers
    Connor, Ashton A. A.
    Kodali, Sudha
    Abdelrahim, Maen
    Javle, Milind M. M.
    Brombosz, Elizabeth W. W.
    Ghobrial, R. Mark
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] PROGNOSTIC FACTORS OF RESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA
    CHOU, FF
    SHEENCHEN, SM
    CHEN, CL
    CHEN, YS
    CHEN, MC
    JOURNAL OF SURGICAL ONCOLOGY, 1995, 59 (01) : 40 - 44
  • [27] Role of Major Vascular Resection in Patients with Intrahepatic Cholangiocarcinoma
    Shahzad M. Ali
    Clancy J. Clark
    Victor M. Zaydfudim
    Florencia G. Que
    David M. Nagorney
    Annals of Surgical Oncology, 2013, 20 : 2023 - 2028
  • [28] Role of Major Vascular Resection in Patients with Intrahepatic Cholangiocarcinoma
    Ali, Shahzad M.
    Clark, Clancy J.
    Zaydfudim, Victor M.
    Que, Florencia G.
    Nagorney, David M.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) : 2023 - 2028
  • [29] Overexpression of CD151 as an Adverse Marker for Intrahepatic Cholangiocarcinoma Patients
    Huang, Xiao-Yong
    Ke, Ai-Wu
    Shi, Guo-Ming
    Ding, Zhen-Bin
    Devbhandari, Ranjan Prasad
    Gu, Fang-Ming
    Li, Quan-Lin
    Dai, Zhi
    Zhou, Jian
    Fan, Jia
    CANCER, 2010, 116 (23) : 5440 - 5451
  • [30] A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma
    Yeh, Chun-Nan
    Wang, Shang-Yu
    Chen, Yen-Yang
    Chen, Ming-Huang
    Chiang, Kun-Chun
    Cheng, Chi-Tung
    Tsai, Chun-Yi
    Wang, Chih-Chi
    Yeh, Ta-Sen
    Chen, Tse-Ching
    ANTICANCER RESEARCH, 2016, 36 (08) : 4249 - 4258